Dacomitinib in advanced lung cancer: Disadvantages outweigh survival advantage
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ...
Aug 19, 2019
0
3